NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed a biomarker for prostate cancer from Epigenomics, which it plans to use to develop a molecular diagnostic test for diagnosing the disease, Epigenomics said today.

The agreement gives Quest the rights to use the GSTP1 DNA methylation biomarker in order to both develop and market the diagnostic test, which will be performed using patient tissue samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.